Company Filing History:
Years Active: 2022-2025
Title: Ingeborg Lues: Innovator in Pharmaceutical Compounds
Introduction
Ingeborg Lues is a notable inventor based in Seeheim-Jugenheim, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as inhibitors of glutaminyl cyclase. With a total of 2 patents, her work is paving the way for advancements in medical treatments.
Latest Patents
Lues' latest patents focus on compounds of formula (I): A-B-D-E or a pharmaceutically acceptable salt, solvate, or polymorph thereof. These compounds are designed to inhibit glutaminyl cyclase (QC, EC 2.3.2.5). The invention details the structural components of these compounds, including various substitutions that enhance their efficacy. The compounds are crucial in catalyzing the intramolecular cyclization of N-terminal glutamine and glutamate residues, which is essential for various biochemical processes.
Career Highlights
Ingeborg Lues is currently associated with Vivoryon Therapeutics N.V., a company dedicated to developing innovative therapies. Her expertise in pharmaceutical chemistry has been instrumental in advancing the company's research initiatives. Lues' work exemplifies the intersection of scientific research and practical application in the pharmaceutical industry.
Collaborations
Throughout her career, Lues has collaborated with esteemed colleagues such as Ulrich Heiser and Torsten Hoffmann. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic compounds.
Conclusion
Ingeborg Lues is a pioneering inventor whose work in pharmaceutical compounds is making a significant impact in the field. Her contributions to the development of glutaminyl cyclase inhibitors highlight her role as a leader in innovation.